The present work aimed at evaluating the potential of intramuscular injection of a hormone-coding gene as an approach for gene therapy in fish. A plasmid containing luteinizing hormone (Lh) in a single-chain (sc) form, pCMVscLh, was chosen as the coding gene, and sea bass was chosen as the target species. In vivo injection of pCMV-scLh in muscle of juvenile sea bass rendered plasma Lh levels higher than 50 ng/ml in 40% of the injected fish, while these Lh levels were only detected in 4% of controls. Injections performed on spermiating broodstock demonstrated that this strategy produced an active Lh able to increase sperm production without affecting its quality, in terms of density. Compared with the injection of a recombinant single-chain Lh, plasmid injection provoked longerlasting and higher plasma Lh levels. These results show that sea bass skeletal muscle is able to uptake plasmid DNA and to secrete the encoded protein to the bloodstream. Therefore, we propose somatic gene transfer as a realistic approach for hormone therapy of dysfunctions due to low hormone levels in fish or just to synchronize spawning.
INTRODUCTION
The use of recombinant or purified native proteins to solve inherited and acquired serum protein deficiencies is widespread in humans. Native proteins are easily cleared from the circulation, and therefore frequent doses have to be administered to produce significant responses. The use of modified recombinant peptides with higher resistance to degradation and longer circulating halflife has been offered as an alternative [1] . However, the availability of purified recombinant proteins has several bottlenecks such as the need for high levels of production, the existence of easy purification methods, and the presence of appropriate posttranslational modifications to ensure their functionality [2] . As a result, the production of such proteins is expensive, their availability can be limited, or their administration inconvenient [3] . One potential avenue for solving problems associated with deficiencies in certain plasma proteins is genebased therapies [4] . Somatic gene transfer technology is based on the introduction and expression of a foreign gene into an adult tissue without being permanently incorporated in the genome or altering the immune system [5] . In 1990, Wolff and coworkers [6] demonstrated the ability of naked DNA to be internalized and expressed when injected into skeletal muscle. Since then, numerous target tissues have been successfully tested for DNA injection [7] . Still, muscle is one of the most attractive sites for therapeutic gene expression. It is an abundant and accessible tissue and has a rich blood supply [8] , making it an efficient system for protein release into the circulation. Regarding vectors to deliver the foreign gene, virus-mediated gene transfer has been the most widely used vector in mammalian applications because it has a high gene transfer rate [9] . However, rather than using viral vectors due to medical complications [10] , the focus has shifted to the use of nonviral vectors, such as naked DNA [11] , as alternatives. Nonviral vector systems, usually based on an expression plasmid, can harbor larger DNA fragments than viral vectors and are easier to prepare, but they pose the problem of low transfer rates. To enhance plasmid DNA uptake by target cells, different physical methods, or chemical carriers, have been tested [11] . Specifically, in vivo DNA electroporation, or electrotransfer, has been used in mice [12] [13] [14] , rats [15, 16] , and dogs [17] to deliver DNA encoding a variety of hormones, cytokines, and enzymes.
To date, naked DNA-based gene therapy has been assayed in mammalian models to solve human diseases caused by deficiencies in circulating proteins, such as hemophilia A and B [17, 18] or chronic anemia [19, 20] , and for hormone deficiencies, such as growth hormone [21, 22] or insulin [23, 24] . In contrast, this technique is scarcely developed in fish, and its application is focused on immunoprophylaxis, mainly to protect against viral infections by injecting the coding sequence of a viral antigenic protein. This approach has been successfully tested in several commercial species such as rainbow trout, Atlantic salmon, Japanese flounder, carp, channel catfish, and turbot (reviewed in [25] ). Indeed, since 2005, a commercial vaccine against infectious hematopoietic necrosis virus (Apex-IHV; Aqua Health Ltd.) is licensed in Canada to treat Atlantic salmon [5] . Another strategy reported for fish vaccination is the injection of a gene construct encoding a neutralizing single-chain antibody [26] , this being the only report in fish where protein secretion into blood has been detected and evaluated. These and other studies using reporter genes in several fish species, such as rainbow trout [27] , zebrafish [28] , Atlantic salmon [29] , glass catfish [30] , and gilthead sea bream [31] , have shown the potential of fish muscle as a target tissue to perform plasmid DNA injections.
Other than the use of this technique for vaccination, where short-term gene expression is sufficient for stimulating an immune response [5] , this methodology can also be used for long-term gene expression to perform systemic treatments as an alternative to continuous administration of native or recombinant hormones. In the last few years, the increasing number of fish genes identified and sequenced has not been followed by a similar development in the production of the corresponding recombinant proteins. This fact has hampered the progress of in vitro and in vivo functional studies in fish and consequently the development of biotechnological strategies similar to those that apply recombinant hormones in biomedicine or to a lesser extent in livestock [32] . Therefore, the aim of this work is to examine for the first time in fish the use of direct gene transfer into muscle as a gene therapy approach for systemic treatments with endocrine hormones. For that, we transiently express a gene coding for single-chain luteinizing hormone (scLh) in sea bass muscle and use a sea bass scLh hormone produced in a eukaryotic cell system as a positive control. We evaluate the ability of fish muscle to secrete the encoded protein into the bloodstream by measuring plasma Lh levels and assess the physiological impact of this recombinant hormone on plasma 11-ketotestosterone (11-KT) levels and sperm production.
MATERIALS AND METHODS

Animals
Juveniles (mean weight: 54 6 4 g) and 3-yr-old European male sea bass (mean weight ¼ 700 6 46 g) were taken from a stock reared at the Instituto de Acuicultura Torre de la Sal. The experiments were performed during the natural reproductive season between December and March under a natural photoperiod condition (408N; 08E). Fish were individualized by the use of passive-integrated transponder tags (Fish Eagle) placed in the intraperitoneal cavity or in the dorsal musculature in juveniles and adults, respectively. Before the treatment, the fish were anesthetized in ethylene glycol monophenyl ether (0.5 ml/L of water). All the experiments were conducted in accordance with the European Union normative use of experimental animals.
Expression Plasmids
The plasmid pCMV-scLh contained an in-frame fusion of the cDNAs coding for the sea bass alpha and Lh-beta subunits linked to the carboxyterminal peptide from human chorionic gonadotropin beta subunit; the plasmid expressed sea bass scLh under the control of the cytomegalovirus (CMV) promoter-enhancer [33] . The plasmid pCMVtk-LacZ contained Escherichia coli beta-galactosidase gene under the control of the CMV enhancer in combination with the thymidine kinase (tk) promoter from the herpes simplex virus [34] .
Production of Recombinant Sea Bass scLh Gonadotropin
Recombinant sea bass scLh was produced by a stable clone of Chinese hamster ovary cells (CHO-K1) that constitutively expresses the pCMV-scLh plasmid [33] . Hormone production was performed as described by Schatz et al. [35] , and the CHO-scLh stable clone was grown in 75-cm 2 flasks to 80%-90% confluence with Dulbecco modified Eagle medium (DMEM) (Invitrogen Corp.) supplemented with 100 units/ml penicillin, 100 lg/ml streptomycin, and 5% fetal bovine serum. Then the media was changed to serum-free Advanced-DMEM (Invitrogen Corp.) containing penicillin, streptomycin, and 1% glutamine, and maintained for 7 days at 258C and 5% CO 2 . The cultured medium was then collected and concentrated using 30-kDa centrifugal filter devices (Centricon Plus-20; Millipore) and later quantified.
Experimental Design and Sampling Procedures
Two experimental trials were conducted to assess the performance of muscle gene transfer as a methodology to deliver gonadotropins.
In experiment one, we examined the effect of intramuscular injection of the pCMV-scLh plasmid on plasma Lh levels in juvenile sea bass. Forty-eight juvenile fish were distributed in three 500-L fiberglass tanks corresponding to three experimental groups: control with no treatment (control group) (n ¼ 12); control injected with pCMVtk-LacZ (LacZ group) (n ¼ 11); and treated fish injected with pCMV-scLh (pscLH group) (n ¼ 25). Because the natural water temperature (14.58C) may be too low for effective plasmid uptake by sea bass muscle, fish were acclimatized at 198C for 1 wk before the experiment and kept at the same temperature thereafter. Anesthetized fish were injected with 100 lg of the corresponding plasmid diluted in 100 ll of 13 phosphate buffer saline (PBS). The DNA was injected rostroventrally to the dorsal fin and above the lateral line using a 26-1/2 gauge needle. Fish were injected twice, at Days 0 (i.e., the day of the first injection) and 3. Blood samples were collected on Days 0 and 3 and then weekly after the first injection until Day 30.
In experiment two, the effects of pCMV-scLh treatment were monitored by evaluating sperm production. Three-year-old spermiating male sea bass were distributed in four 500-L fiberglass tanks, corresponding to four experimental groups: not treated (control group) (n ¼ 9); fish injected with pCMVtk-LacZ, the LacZ group, (n ¼ 9); fish injected with pCMV-scLh, the pscLH group, (n ¼ 12); and a positive control receiving recombinant scLh (scLH group) (n ¼ 11). The pscLH and LacZ groups received two intramuscular injections, at Days 0 and 3, with 200 lg/fish of plasmid diluted in 150 ll of 13 PBS. To ensure uniform and enhanced plasmid uptake, eight square electroporation pulses of 100 V/cm of 20 msec duration were applied to the pscLH and LacZ groups around the injected area immediately after the DNA injection. Needle arraytype electrodes (2-needle array model 531; BTX) and the ECM 830 (BTX) generator were used. The scLH group also received two intramuscular injections at Days 0 and 3 with 200 ng/fish of recombinant hormone in 150 ll 13 PBS. During the experiment, the seawater temperature was natural for the scLH group (148C 6 28C), while the control, LacZ, and pscLH groups were maintained at 178C from 1 wk before the first injection until the end of the trial to ensure DNA uptake. This temperature does not affect sea bass reproduction [36] . Blood samples were obtained at Days 0 and 3 and then weekly until Day 34. Sperm samples were collected 2 days before the first injection and weekly until Day 34. This period largely covers the time of response to spermiation induction already reported in sea bass [37, 38] . Before sperm collection, the genital area was cleaned with fresh water and thoroughly dried. Milt was stripped by abdominal massage and collected in a 15-ml graduated tube coupled to a vacuum pump. The semen was maintained at 48C until use.
In both experiments, blood was collected from anesthetized fish by caudal puncture, and plasma was obtained by centrifugation (2500 3 g, 30 min at 48C) and stored at À208C until hormone analysis.
Hormone Analysis
Recombinant hormone quantification and plasma Lh levels were determined using a validated enzyme-linked immunoassay for sea bass [39] . The detection limit was 0.65 ng/ml (bounded input/bounded output ¼ 80%). In adult males, plasma levels of 11-KT were analyzed by enzyme immunoassay according to [40] . The sensitivity of the assay for 11-KT was 1.75 pg/well.
Analysis of Milt
Determination of milt density was performed immediately after collection. To avoid sperm aggregation and to achieve an appropriate concentration, milt was diluted 1:2000 with extender for sea bass sperm [41] . To analyze sperm density, 2 ll of the mixture were deposited in a Neubauer-type slide and observed using a 203 negative phase contrast objective (Nikon Plan Fluor) on an Eclipse E400 Nikon microscope. A Sony CCD-IRIS video camera transferred the image that was recorded for later analysis by the (L) Integrated Semen Analysis System (PRO-ISER RþD).
Statistics
Data were analyzed using Sigma Stat 3.5 (SPSS Inc.). The results were expressed as mean 6 SEM. Data were checked for normal distribution using a Kolgomorov-Smirnoff test following logarithmic transformation (as required), and a Bartlett test was used to establish homogeneity of the variances. Data of Lh, 11-KT levels, and sperm density were analyzed by two-way ANOVA followed by all pairwise multiple comparison procedures (Holm-Sidak method). Data of milt production is expressed as the sum of the average milt volume per body weight collected in each sampling point. It was analyzed by the chi-square test. Differences were considered to be statistically significant when P , 0.05.
RESULTS
Plasma Lh Secretion in scLh Plasmid-Injected Animals
To determine the ability of muscle cells to produce and secrete into the bloodstream the hormone encoded by pCMVscLh and furthermore to assess whether physiologically significant hormone plasma levels could be attained, juvenile sea bass were injected with the mentioned plasmid and their plasma Lh levels were analyzed.
Three days after the first injection, some pscLH fish showed a significant increase in plasma Lh content. However, the MAZÓ N ET AL. maximum Lh levels in the pscLH group were observed at Days 7, 14, and 20 ( Fig. 1) . Thereafter, a significant reduction was detected on Day 30, attaining Lh levels similar to the control groups. On the other hand, the control and LacZ groups showed no change in their Lh levels throughout the experiment (Fig. 1) . The individual tagging of fish allowed us to evaluate the Lh secretion dynamics in each fish and also to identify failed injections. Thus, among pscLH individuals, a high variability in plasma Lh levels was observed in response to the injection. This included fish showing Lh plasma levels one to two orders of magnitude higher than the control fish, while others were in the same range as the controls. We detected that about 58% of the control fish showed plasma Lh levels under 10 ng/ml, while only 4% reached Lh levels higher than 50 ng/ ml. Among the pscLH-treated fish, 44% presented a range of 20-100 ng of Lh/ml and 24% had Lh values higher than 100 ng/ml.
Changes in Plasma Lh Levels in Injected Adults
Once we demonstrated that intramuscular injection of the pCMV-scLh plasmid resulted in an increase in circulating Lh levels in juveniles, we evaluated this approach in reproductively active adult male fish. Furthermore, we wanted to compare the bioavailability of the plasmid-encoded hormone with that of injected recombinant Lh. Thus, we established four different groups injected with pCMV-scLh, pCMVtk-LacZ, or recombinant scLh protein, and noninjected fish. We applied electroporation pulses after injection with the aim of reducing the variability in DNA uptake observed in juvenile fish ( Fig. 1 and Table 1 ), taking into account that DNA uptake and expression is less efficient in large than in small fish [42] .
Plasma Lh levels in the adult male groups are shown in Figure 2 . In the controls, Lh levels were high during the first week, as expected in spermiating sea bass [43, 44] . Treatment with recombinant scLh and with pCMV-scLh yielded higher plasma Lh levels than the control groups and different profiles. In the pscLH group, a significant increase in plasma Lh was observed, ranging from 0.84 6 0.3 ng/ml at Day 0 to 8.97 6 1.36 ng/ml at Day 13, when the highest levels were attained. Thereafter, the values decreased although they were still significantly higher than the other groups 34 days after the first 
FIG. 2. Hormone levels in adult sea bass. A) Plasma Lh levels (ng/ml). B)
Plasma 11-ketotestosterone levels (ng/ml). Hormonal values are the mean 6 SEM of 7 to 14 fish. Different letters denote significant differences among treatments at each sampling point (P , 0.05, one-way ANOVA). Control, not injected; LacZ, pCMVtk-LacZ injected; scLh, treated with recombinant scLh; pscLh, pCMV-scLh injected. The days of injection are indicated with an asterisk.
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injection. In scLh-treated fish, the initial Lh values of 4.6 6 0.8 ng/ml increased at Day 6 and showed maximum levels of 6.8 6 0.6 ng/ml at Day 13; the levels then fell down to about 2 ng/ml on successive days. Control fish showed the same profile of Lh levels: a nonsignificant increment from Day 0 to Day 6, followed by a significant decrease at Day 13; thereafter, the levels remained low until the end of the trial. In vivo electroporation of the adult animals dramatically reduced the variability in the response to plasmid treatment. Table 1 shows in percentage the responsive and nonresponsive fish in both experiments. Electroporation generated a 100% positive response from Day 14 till the end of the trial in adult males. In the case of juvenile fish, the highest percentage of responsive animals was obtained at Day 7 (60%).
Functional Effect of Muscle-Produced Lh
Once it was shown that the hormone synthesized by the muscle cells could reach the bloodstream also in adults, a relevant point was to evaluate whether this hormone had physiological effects. The key role of Lh on male fish reproduction and specifically in sea bass is to regulate the final steps of germ cell maturation and spermiation [45, 46] , and thus we evaluated the effect of recombinant scLh and pCMV-scLh plasmid injections on milt production and milt density in treated adult male fish. The total volume of milt collected during the experiment is shown in Figure 3A . Both the scLH and pscLH groups were equally efficient in inducing milt production: in both groups, a significant increase occurred compared to the controls. Besides, the injections of scLh and pCMV-scLh generated a significant increase in sperm density with respect to the control groups (Fig. 3B) , however, no differences were found between the Lh treatment groups.
In addition, plasma 11-KT levels were measured in the adult fish groups before the injections and during the whole experiment to assess the potential effect of recombinant Lh on 11-KT production. All the groups showed a similar profile (Fig. 2B) . The levels of 11-KT were high at the onset of the experiment and declined continuously, reaching basal levels at the end of the spermiation period; no statistical differences among experimental groups were observed during the whole period.
DISCUSSION
This work presents for the first time, to our knowledge, a physiological application of gene therapy in fish. We demonstrate the efficient delivery into the bloodstream of a physiologically active recombinant hormone after the injection of its coding sequence in muscle. To evaluate the effectiveness of this methodology in fish we used sea bass Lh as the genetic sequence and sea bass skeletal muscle as the target organ. First, injections in juvenile sea bass showed that muscle cells could take up scLh-expression plasmid and synthesize and release Lh into the systemic circulation. However, the response to the DNA injection varied greatly among the fish. Next, injection of the same plasmid to reproductively active males demonstrated that the Lh produced by the muscle cells was biologically active. Application of in vivo electroporation after injection resulted in a higher percentage of fish that responded to DNA injection, thus, reducing the variability observed in the injected juvenile fish.
In fish, previous reports using reporter genes [29, 31] have shown the persistence of gene expression in muscle after intramuscular injection of an expression plasmid; in addition, this technique has been oriented toward prophylactic applications (reviewed in [5] ). There is only one study related to vaccination with a clear strategy of secreting into the bloodstream the product encoded in the injected plasmid, that of Lorenzen et al. [26] who injected a gene coding for a neutralizing single-chain antibody to VHSV (viral hemorrhagic septicemia virus) into trout muscle. This antibody was detected thereafter in the serum and conferred specific protection against VHSV.
In our experiment with juvenile fish, variable responses to plasmid injection were detected among the animals. To obtain more uniform results in the adult group, we decided to apply square electroporation pulses after injection because, as previously shown, electroporation improved the expression of injected genes in adult sea bass in the winter (Muñoz, Zanuy, Mazón, Carrillo, and Gómez, unpublished results). In vivo electroporation of fish tissues to increase cell permeability to DNA has only been assayed in zebrafish, but the electroporation device was very different from the one used in this work [47] [48] [49] . Thus, both the difference in size between zebrafish and sea bass and the use of distinct electrode types make it difficult to extrapolate the conditions. In view of the absence of a standard protocol for electrotransfer in fish and taking into   FIG. 3 . A) Total milt collected (ml/kg) during the experiment. Data are represented as the mean 6 SEM. Different letters denote statistical significance (P , 0.05, chi-square test). B) Sperm density in spermatozoa per milliliter (spz/ml). Data are the mean 6 SEM. Different letters indicate significant differences between treatments (P , 0.05, one-way ANOVA, Holm-Sidak method). Groups: control, not injected; LacZ, pCMVtk-LacZ injected; scLh, treated with recombinant scLh; pscLh, pCMV-scLh injected.
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account that high electric field intensities can cause cell necrosis and decreased gene expression [50] , we decided to deliver fewer pulses at a lower voltage (eight pulses at 100 V/ cm). With this electroporation protocol, we reduced interindividual variability, obtaining a uniform response to the plasmid DNA injections. Alternative conditions could also be assessed in the future, as some authors [51] propose the use of highvoltage and short-pulse currents to provide long-lasting gene expression in muscle.
In this study, all the fish injected with pCMV-scLh showed significant increases in Lh plasma levels when compared to the control animals. Nevertheless, differences in maximum Lh plasma level and in the time-response were found between adult and juvenile groups. About 68% of the pscLH juvenile fish reached plasma Lh levels higher than 20 ng/ml, and some of them achieved the highest hormone levels already at 7 days after first the injection. In the case of adults, the maximum concentration detected was 17 ng Lh/ml, which was lower than the levels in juveniles but enough to increase sperm release. The differences in plasma Lh found between juvenile and adult fish could be explained by the relative quantity of injected plasmid. The relation of injected DNA per body weight was much lower in adult animals (0.57 lg of DNA/g of body weight) than in juveniles (4 lg of DNA/g of body weight). In addition, it has been described that gene expression after plasmid injection is significantly less efficient in large than in small fish [42] , as reported for other animals [52] . This fact is correlated with a greater diffusional path length in the myofibers of large animals, taking longer for the plasmid molecules to enter the nucleus. On the other hand, several works suggest that electrotransfer can prolong the expression period, increase DNA uptake into cells [18, 51] , and augment the expression 100-to 1000-fold [53] , consequently improving the efficiency of plasmid injection. In our study, Lh plasma content in electroporated animals was still significantly higher than in controls 1 mo after injection; in contrast, in the same time period, Lh was near basal levels in nonelectroporated fish. This fact indicates that electroporation could influence the duration of the gene effect, although this statement is valid only when comparing animals of the same size.
One of the most outstanding differences when comparing the injection of the pCMV-scLh plasmid with direct administration of the recombinant protein is the persistence of the scLh in the bloodstream. Sea bass scLh produced in mammalian cells was chosen for injection because previous studies by our group showed that it had a longer in vivo half-life than other recombinant forms and was bioavailable in the bloodstream in less than 1 h after injection [33] . In this study, injection of this recombinant scLh resulted in maximum levels of plasma Lh between 6 and 13 days after the first injection. Thereafter, because of metabolic clearance, its presence in plasma was drastically reduced to basal levels. A different dynamics was observed in the case of the scLh plasmid treatment. The time required for plasmid uptake by the muscle cells and subsequent synthesis and blood release of the protein resulted in a steady increase of Lh during the first week after injection, giving the first significant rise at Day 13. Secretion of the hormone by the plasmid-injected muscle cells could be detected up to 30 days, in contrast to the 13 days obtained after scLH administration, showing the advantage of this approach for long-lasting treatments. The prolonged production of Lh by muscle cells in sea bass is in agreement with observations described in mammals (reviewed in [50] ). Injection of plasmids encoding erythropoietin (EPO) [54] or human-alpha-1-antitrypsin [52] into mice yielded a peak of the corresponding recombinant protein in serum 7 days after injection; protein levels started to decline by Day 14 and were barely detectable by Day 21. Longer-lasting effects have also been observed in mice where significantly high EPO plasma levels were detected 90 and 140 days after EPO-coding plasmid injection [3, 55] . Indeed, obtainment of a sustained gene expression is still one of the major goals in nonviral gene therapy. Construct design or delivery can influence the efficiency of this method, showing that there is still room for improvement. Thus, in mammals, the incorporation of intron sequences into the plasmid dramatically increased the duration of gene expression [56] , and the injection of a linear DNA expression cassette produced 10-to 100-fold higher expression levels than the equivalent circular DNA when injected in the liver of mice [57] . Accordingly, further studies need to be performed in fish to understand the process of DNA uptake, which will allow the design of more effective plasmids with higher and longer expression rates.
Treatment of adult male sea bass with pCMV-scLh or scLh resulted in an increase in sperm production, which confirmed the in vivo bioactivity of this recombinant hormone and strengthened the case for the involvement of Lh in spermiation in this species. Our group had previously demonstrated that in sea bass treated with GnRHa the increase in sperm release is in parallel with an increase in Lh plasma levels [44] , which is similar to the findings in other fish species [58, 59] . Indeed, injection of the Lh plasmid resulted in sustained Lh levels similar to those obtained with GnRHa slow-release implants [44] as evidenced by the significantly higher plasma Lh levels in treated versus control fish seen until the end of the sampling period (34 days). In addition, the total milt collected was more than double in treated fish, both scLh protein and plasmid, than in control fish. This is in the range of the milt production obtained with different GnRHa-releasing devices in sea bass [37] . It is remarkable that the increase in sperm release did not alter its quality, in terms of density, showing levels similar to those obtained by Sorbera et al. [37] . This is an important issue to consider for a maturation-inducing method, and because the methodology used in the present work is more direct in its action than the use of GnRHa, we consider that our approach could be suitable to induce gonad maturation and spawning.
Contrary to the scLh effects on sperm production, no increase in plasma 11-KT was found in scLH-treated animals. Indeed, the initial 11-KT levels declined in all the animals during the experiment independently of the treatment. This profile highly resembles that shown by Mañanós et al. [44] after different GnRHa treatments were used to induce spermiation in sea bass and reinforces the conclusion that this hormone is not important in this process. However, we had previously demonstrated that Lh is able to enhance 11-KT production in sea bass testis cultured in vitro [33] . This discrepancy between both studies is probably dependent on the stage of testicular maturation, that is, while Lh treatment of late-spermatogenic testis stimulated 11-KT production in our in vitro study, administration of this gonadotropin is unable to enhance 11-KT production in spermiating testis. The absence of a role for 11-KT in supporting spermiation in sea bass agrees with the findings in other species [60] .
Despite the large amount of fish genes isolated in the last years, few fish recombinant proteins have been produced to date, mainly because of the complexity of their production. Therefore, basic research on their function, regulation, and biological application in fish has been frequently delayed compared to the large number of studies on gene expression. In any case, positive results have been obtained in the few fish species that have been injected in vivo with homologous recombinant gonadotropins. These treatments were able to LUTEINIZING HORMONE GENE THERAPY IN SEA BASS influence both steroid production and gonad development (reviewed in [61] ). Somatic gene transfer using plasmid vectors, as shown here, can be an inexpensive and easy alternative to the use of native or recombinant hormones. Plasmid vectors are simple to construct, and their production is easily scaled up [53] . In addition, plasmid DNA can be efficiently taken up by the cells with a negligible rate of integration into the genome [62] .
As demonstrated here, somatic transfer of a DNA coding for a single-chain gonadotropin could be used as gene therapy to solve reproductive dysfunctions associated with low hormone levels. In addition, return to pretreatment hormone levels 3 wk after cessation of therapy suggests that repeated delivery of a gonadotropin plasmid could be used as a long-term treatment for gonadotropin deficiencies. In conclusion, compared with the production of recombinant hormones, the low cost of production and higher persistence of plasmid DNA shows the potential of this system for in vivo research and also as a gene therapy methodology to remedy reproductive dysfunctions or to synchronize spawning in aquaculture fish species.
